Stephens analyst Jeff Garro initiated coverage of Health Catalyst with an Equal Weight rating and $13 price target. The analyst believes Health Catalyst has a "large and sticky opportunity to capitalize on a healthcare industry slowly realizing the need for a commercial-grade data/analytics solution beyond the EHR," and still sees room for long term expectations to fully reset. "Better visibility into an improving end market" would make the firm more constructive.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCAT:
- Health Catalyst announces partnership with Contexture
- Health Catalyst upgraded to Overweight from Equal Weight at Wells Fargo
- Health Catalyst price target lowered to $16 from $17 at Citi
- Health Catalyst to Participate in Upcoming Investor Conference
- Health Catalyst price target raised to $13 from $11 at Wells Fargo
